Cancer of the hepatobiliary system among the population of the Tyumen region

Liver cancer is a serious disease, the frequency of which is steadily growing in many countries of the world, and the incidence and mortality reaches more than one million people a year. In the Tyumen region in 2018, a total of 113 cases of liver and intrahepatic biliary tract cancer were detected (men - 63,3%, women - 36,7%). Of these, stage 1 is 4.1%, stage 2 is 5.2%, stage 3 is 22,7%, and stage 4 is 68,0%. Thus, the share of running forms (3 and 4 stages) is 90,7%. Mortality in the first year - 68,7%. In total, 98 people died in the Tyumen region in 2018, 66,6% of them - men, 29,% - women. Five-year survival rate is 22,9%. Of 113 cases in the Tyumen region, only 7,4% were detected actively, i.e. as a result of screening programs. This indicates poor coverage of screening studies for active detection of cancer of the hepatobiliary system. Hepatocellular carcinoma is the most common primary liver tumor with an aggressive course and an unfavorable prognosis in the world. Recently, for differential diagnosis are increasingly began to use glypican-3. The independent value of glipican-3 for the diagnosis of hepatocellular carcinoma is limited. It is increased in 1/3 of patients with normal levels of alpha-fetoprotein in the blood. The lack of correlation between these biomarkers gives grounds for their combined use, which increases the efficiency to 76% for tumors smaller than 3 cm.